MarketCapTrends
FATE

Fate Therapeutics Inc. (FATE)

NASDAQ · Healthcare

Fate Therapeutics Inc. annual/quarterly shareholder equity history from 2012 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Fate Therapeutics Inc. shareholder equity for the quarter ending December 31, 2025 were 207.2M, a 35.00% decrease year-over-year.
  • Fate Therapeutics Inc. shareholder equity for 2025 were 207.2M, a 35.00% decrease from 2024.
  • Fate Therapeutics Inc. shareholder equity for 2024 were 318.7M, a 13.49% decrease from 2023.
  • Fate Therapeutics Inc. shareholder equity for 2023 were 368.4M, a 23.87% decrease from 2022.
  • Fate Therapeutics Inc. shareholder equity for 2022 were 483.9M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Fate Therapeutics Inc. Annual Shareholder Equity (Millions of US $)
2025$207
2024$319
2023$368
2022$484
2021$679
2020$384
2019$245
2018$160
2017$77
2016$73
2015$38
2013$51
2012$-53
Fate Therapeutics Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$207
2024-12-31$319
2023-12-31$368
2022-12-31$484
2021-12-31$679
2020-12-31$384
2019-12-31$245
2018-12-31$160
2017-12-31$77
2016-12-31$73
2015-12-31$38
2013-12-31$51
2012-12-31$-53

Fate Therapeutics Inc. Shareholder Equity — FAQ

Fate Therapeutics Inc. (FATE) shareholder equity over the last 14 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see FATE's shareholder equity history?

The chart and table above show Fate Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.